A recent review highlights the interplay between the pathology of insulin resistance and sarcopenia, with emphasis on several well-studied molecular targets, including the mechanistic/mammalian target of rapamycin (mTOR) (a primary regulator of protein synthesis) and Akt (a central node in insulin signaling), among others [1]. Here, MTOR is linked to sarcopenia.